Floatz Rating
B61/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03136146CT.gov Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | — | Recruiting | — | — | — |
NCT03117751CT.gov Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01700946CT.gov Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | — | Completed | — | — | — |
NCT01842672CT.gov Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia | — | Completed | — | — | — |
NCT01451515CT.gov NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT00412243CT.gov Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clofarabine (this asset) | M.D. Anderson Cancer Center | P2/3 | B · 61 |
| Rituximab | University of Washington | P4 | BBB |
| Cladribine | Fifth Affiliated Hospital, Sun Yat-Sen University | P4 | BBB |
| Vindesine | University Hospital Muenster | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| Mercaptopurine Anhydrous | City of Hope Medical Center | P4 | BBB |
| Pegaspargase | Chongqing Peg-Bio Biopharm Co., Ltd. | P4 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BB |
| Adriamycin | University of Washington | P4 | BB |
+42 more in the Lymphoblastic Lymphoma cohort
Other indications for Clofarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 70 |
| Acute Myeloid Leukemia, Del(5q31-Q32) | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clofarabine in Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clofarabine-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →